Doxapram
Brand names: Dopram
Doxapram is an intravenous central respiratory stimulant used under close supervision in selected cases of acute respiratory failure, such as ventilatory failure where assisted ventilation is not appropriate. It is a short-term measure given in a monitored setting.
ClinCalc Pro is rebuilding its dose data from primary open sources — the manufacturer SmPC (eMC), the WHO Model Formulary and other official references — under clinician review. This drug's structured dose is not yet published here. Confirm all doses against the product SmPC and your local formulary before prescribing.
Clinical monograph
How it works
It stimulates respiration through an action on peripheral chemoreceptors and, at higher doses, the central respiratory centres, increasing tidal volume and respiratory rate. The effect is brief, reflecting its short duration of action.
Prescribing in practice
- It has a narrow margin of safety and can cause agitation, hypertension, arrhythmias, and convulsions, so it must be given with continuous cardiorespiratory monitoring and is contraindicated in severe hypertension, epilepsy, and obstructive airways disease with severe airflow limitation.
- It is unsuitable where the increased work of breathing cannot be sustained, such as severe airflow obstruction or exhaustion.
- Use with great caution alongside other CNS stimulants and where coronary artery disease is present.
Monitoring
Maintain continuous monitoring of blood pressure, heart rhythm, oxygenation, and blood gases during the infusion.
Counselling the patient
- This is a hospital-only treatment given by drip under close observation.
- Staff will watch your breathing, heart, and blood pressure throughout.
- Tell staff at once if you feel agitated, breathless, or have palpitations.
Evidence & guidelines
Doxapram retains a limited specialist role as a respiratory stimulant in acute ventilatory failure when ventilatory support is not appropriate, used with intensive monitoring.
Reference: NICE; BTS/SIGN COPD Guidelines; Drug verified in RxNorm (NLM); confirm dosing against the manufacturer SPC (eMC). Verify against your local formulary and current prescribing references before prescribing. Monograph status: clinician-reviewed (2026-07-04).
Related
Curated clinical cross-links plus same-class fallbacks.
- P/F Ratio (Horowitz Index) · Respiratory Assessment
- Murray Score for Acute Lung Injury (ALI/ARDS) · Respiratory Failure
- CURB-65 Score for Pneumonia · Infection
- Lower Respiratory Tract Infection (LRTI) Severity Score · Pneumonia / LRTI
- Silverman-Andersen Retraction Score · Respiratory Distress
- CPAP Initiation Criteria (Neonatal) · Respiratory Support
- Acute Asthma in Adults · BTS/SIGN British Guideline on Asthma 2019; NICE NG80
- Pulmonary Embolism Assessment · NICE NG158; ESC 2019 PE Guidelines
- Acute Exacerbation of COPD (AECOPD) · NICE NG115; GOLD 2024
- Spontaneous Pneumothorax (Adult) · BTS Pleural Disease 2023
- Atypical Pneumonia (Legionella / Mycoplasma / Chlamydophila) · BTS 2023; IDSA
- COPD Exacerbation Management · NICE NG115 / GOLD 2024